Given the potent antiproliferative, proapoptotic, and antiangiogenic activities of SSTR3, targeting this receptor with a multireceptor SSA such as pasireotide may be potentially beneficial in treating aggressive nonfunctioning pituitary adenoma [12, 13]. The gene discussed is SSTR3; the disease is pituitary gland adenoma.